Skip to main content
SpringerLink
Log in

Racial Disparities and the Global Picture

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2935 Accesses

Abstract

Epidemiologic studies in prostate cancer have evaluated the impact of race and geographic location on prostate cancer risk and outcomes, with the goal of further understanding risk factors, molecular mechanisms, and the impact of potential differences in practice patterns between populations. Important epidemiologic differences in prostate cancer incidence and mortality have been discovered between different ethnicities and geographic regions with African American men (AAM) having one of the highest reported incidence rates in the world as well as much higher prostate cancer-specific mortality rates than European American men (EAM). These data raise the following questions which are currently under investigation: (1) Are these differences representative of inherent environmental or biologic differences between ethnic groups? (2) Are they representative of different screening and treatment patterns between populations? and (3) Are they simply artifacts of data collection and cancer registry accuracy (i.e., increased attribution of mortality to prostate cancer due to increased detection)? If the answer to any of these questions is “yes,” how can we use this information to improve our knowledge and better prevent and treat prostate cancer in all men? Each of these questions is addressed in this chapter, with particular attention to the first two questions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Giri VN, Egleston B, Ruth K, et al. Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila). 2009;2(3):244–50.

    Article  CAS  Google Scholar 

  2. Sloane, D. Cancer Epidemiology in the United States: Racial, Social, and Economic Factors. In: Methods in Molecular Biology, Cancer Epidemiology, vol. 471. Verma, M (ed.). Book 10.1007/978-1-59745-416-2

  3. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975–2007. http://seer.cancer.gov/csr/1975_2007/. Accessed on March 10, 2011.

  4. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866–71.

    PubMed  Google Scholar 

  5. GLOBOCAN 2008. International agency for research on cancer. http://globocan.iarc.fr/. Accessed on March 10, 2011.

  6. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. Nig Q J Hosp Med. 2009;19(3):145–7.

    PubMed  CAS  Google Scholar 

  7. Ajape AA, Ibrahim KO, Fakeye JA, Abiola OO. An overview of cancer of the prostate diagnosis and management in Nigeria: the experience in a Nigerian tertiary hospital. Ann Afr Med. 2010;9(3):113–7.

    Article  PubMed  Google Scholar 

  8. Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999;91(3):159–64.

    PubMed  CAS  Google Scholar 

  9. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82(9):1585–92.

    Article  PubMed  CAS  Google Scholar 

  10. Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4 Suppl 1:S2.

    Article  PubMed  Google Scholar 

  11. Curado M, Edwards B, Shin H, et al. Cancer incidence in five continents, vol. IX. Lyon: IARC Scientific Publications; 2007.

    Google Scholar 

  12. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991–2006. Int J Cancer. 2010;126(5):1187–95.

    PubMed  CAS  Google Scholar 

  13. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–7.

    Article  PubMed  CAS  Google Scholar 

  14. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 1996;30(2):138–44.

    PubMed  CAS  Google Scholar 

  15. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150(2 Pt 1):379–85.

    PubMed  CAS  Google Scholar 

  16. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977;20(5):680–8.

    Article  PubMed  CAS  Google Scholar 

  17. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health. 2003;93(10):1753–9.

    Article  PubMed  Google Scholar 

  18. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer. 1992;70(8):2152–8.

    Article  PubMed  CAS  Google Scholar 

  19. Roetzheim RG, Pal N, Tennant C, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91(16):1409–15.

    Article  PubMed  CAS  Google Scholar 

  20. Freedland SJ, Dorey F, Aronson WJ. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy. Urology. 2000;56(5):807–11.

    Article  PubMed  CAS  Google Scholar 

  21. Freeman VL, Leszczak J, Cooper RS. Race and the histologic grade of prostate cancer. Prostate. 1997;30(2):79–84.

    Article  PubMed  CAS  Google Scholar 

  22. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology. 2000;55(5):730–5.

    Article  PubMed  CAS  Google Scholar 

  23. Jani AB, Vaida F, Hanks G, et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001;96(6):363–71.

    Article  PubMed  CAS  Google Scholar 

  24. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177(2):444–9.

    Article  PubMed  Google Scholar 

  25. Evans S, Metcalfe C, Patel B, et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer. 2010;102(2):249–54.

    Article  PubMed  CAS  Google Scholar 

  26. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol. 2002;168(6):2510–5.

    Article  PubMed  Google Scholar 

  27. Iselin CE, Box JW, Vollmer RT, Layfield LJ, Robertson JE, Paulson DF. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer. 1998;83(11):2353–60.

    Article  PubMed  CAS  Google Scholar 

  28. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155(5):1667–73.

    Article  PubMed  CAS  Google Scholar 

  29. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59(6):907–12.

    Article  PubMed  Google Scholar 

  30. Powell IJ, Banerjee M, Bianco FJ, et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol. 2004;171(4):1508–12.

    Article  PubMed  Google Scholar 

  31. Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc. 1998;90(2):101–4.

    PubMed  CAS  Google Scholar 

  32. Bennett CL, Ferreira MR, Davis TC, et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16(9):3101–4.

    PubMed  CAS  Google Scholar 

  33. Conlisk EA, Lengerich EJ, Demark-Wahnefried W, Schildkraut JM, Aldrich TE. Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. Urology. 1999;53(6):1194–9.

    Article  PubMed  CAS  Google Scholar 

  34. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106(6):1276–85.

    Article  PubMed  Google Scholar 

  35. Howard G, Anderson RT, Russell G, Howard VJ, Burke GL. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol. 2000;10(4):214–23.

    Article  PubMed  CAS  Google Scholar 

  36. Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56(6):1016–20.

    Article  PubMed  CAS  Google Scholar 

  37. Vijayakumar S, Weichselbaum R, Vaida F, Dale W, Hellman S. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996;2(4):225–33.

    PubMed  CAS  Google Scholar 

  38. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58(1):9–31.

    Article  PubMed  Google Scholar 

  39. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating black-white differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123(2):430–5.

    Article  PubMed  CAS  Google Scholar 

  40. Eastham JA, Carver B, Katz J, Kattan MW. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men. Prostate. 2002;50(4):236–40.

    Article  PubMed  Google Scholar 

  41. Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95(22):1702–10.

    Article  PubMed  Google Scholar 

  42. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1998;90(13):986–90.

    Article  PubMed  CAS  Google Scholar 

  43. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171(4):1504–7.

    Article  PubMed  Google Scholar 

  44. Cowen ME, Kattan MW, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer. 1996;78(9):1952–7.

    Article  PubMed  CAS  Google Scholar 

  45. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 national health interview survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3):636–44.

    Article  PubMed  Google Scholar 

  46. Scales Jr CD, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer. 2008;113(6):1315–23.

    Article  PubMed  Google Scholar 

  47. Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.

    Article  PubMed  CAS  Google Scholar 

  48. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;v 360(13):1320–8.

    Article  PubMed  Google Scholar 

  49. Penson DF, Chan JM. Urologic diseases in America. Washington, D.C.: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.

    Google Scholar 

  50. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996;34(2):152–62.

    Article  PubMed  CAS  Google Scholar 

  51. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13(1):93–100.

    PubMed  CAS  Google Scholar 

  52. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93(24):1864–71.

    Article  PubMed  CAS  Google Scholar 

  53. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003;18(10):845–53.

    Article  PubMed  Google Scholar 

  54. Horner RD. Racial variation in cancer care: a case study of prostate cancer. Cancer Treat Res. 1998;97:99–114.

    Article  PubMed  CAS  Google Scholar 

  55. Imperato PJ, Nenner RP, Will TO. Radical prostatectomy: lower rates among African-American men. J Natl Med Assoc. 1996;88(9):589–94.

    PubMed  CAS  Google Scholar 

  56. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36(9):1337–48.

    Article  PubMed  CAS  Google Scholar 

  57. Lai S, Lai H, Krongrad A, Lamm S, Schwade J, Roos BA. Radical prostatectomy: geographic and demographic variation. Urology. 2000;56(1):108–15.

    Article  PubMed  CAS  Google Scholar 

  58. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88(5):1122–30.

    Article  PubMed  CAS  Google Scholar 

  59. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64(6):1171–6.

    Article  PubMed  Google Scholar 

  60. Talcott JA, Spain P, Clark JA, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer. 2007;109(8):1599–606.

    Article  PubMed  Google Scholar 

  61. Carpenter WR, Howard DL, Taylor YJ, Ross LE, Wobker SE, Godley PA. Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control. 2010;21(7):1071–80.

    Article  PubMed  Google Scholar 

  62. Shavers VL, Brown M, Klabunde CN, et al. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care. 2004;42(3):239–50.

    Article  PubMed  Google Scholar 

  63. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(2):121–6.

    PubMed  CAS  Google Scholar 

  64. Kubricht 3rd WS, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54(6):1035–8.

    Article  PubMed  Google Scholar 

  65. Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171(6 Pt 1):2277–80.

    Article  PubMed  CAS  Google Scholar 

  66. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76(1):45–8.

    PubMed  CAS  Google Scholar 

  67. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339(8798):887–9.

    Article  PubMed  CAS  Google Scholar 

  68. Devgan SA, Henderson BE, Yu MC, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate. 1997;33(1):9–12.

    Article  PubMed  CAS  Google Scholar 

  69. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55(18):3973–5.

    PubMed  CAS  Google Scholar 

  70. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol. 2000;25(1):85–96.

    Article  PubMed  CAS  Google Scholar 

  71. Gaston KE, Kim D, Singh S, Ford 3rd OH, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170(3):990–3.

    Article  PubMed  CAS  Google Scholar 

  72. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.

    Article  PubMed  CAS  Google Scholar 

  73. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  PubMed  CAS  Google Scholar 

  74. Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668–75.

    Article  PubMed  CAS  Google Scholar 

  75. Giri VN, Ruth K, Hughes L, et al. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int. 2011;107:466–70.

    Article  PubMed  CAS  Google Scholar 

  76. Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70(13):5207–12.

    Article  PubMed  CAS  Google Scholar 

  77. Miyagi Y, Sasaki T, Fujinami K, et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol. 2010;23(11):1492–8.

    Article  PubMed  Google Scholar 

  78. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control. 1996;7(1):83–4.

    Article  PubMed  CAS  Google Scholar 

  79. Marks LS, Kojima M, Demarzo A, et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology. 2004;64(4):765–71.

    Article  PubMed  Google Scholar 

  80. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev. 2003;61(4):117–31.

    Article  PubMed  Google Scholar 

  81. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63(6):963–6.

    Article  PubMed  CAS  Google Scholar 

  82. Angwafo FF. Migration and prostate cancer: an international perspective. J Natl Med Assoc. 1998;90(11 Suppl):S720–3.

    PubMed  CAS  Google Scholar 

  83. Miller G. Prostate cancer among the Chinese: pathologic, epidemiologic, and nutritional considerations. London: BC Decker; 2000.

    Google Scholar 

  84. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3–12.

    Article  PubMed  Google Scholar 

  85. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.

    Article  PubMed  Google Scholar 

  86. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13(1):R103–21.

    Article  PubMed  CAS  Google Scholar 

  87. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87(9):652–61.

    Article  PubMed  CAS  Google Scholar 

  88. Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 1996;16(2):815–20.

    PubMed  CAS  Google Scholar 

  89. Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8(1):25–34.

    PubMed  CAS  Google Scholar 

  90. Amling CL, Kane CJ, Riffenburgh RH, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58(5):723–8.

    Article  PubMed  CAS  Google Scholar 

  91. Buschemeyer 3rd WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52(2):331–43.

    Article  PubMed  Google Scholar 

  92. McGreevy K, Hoel B, Lipsitz S, Bissada N, Hoel D. Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. Urology. 2005;66(3):587–92.

    Article  PubMed  Google Scholar 

  93. Platz EA, Pollak MN, Rimm EB, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1107–10.

    PubMed  CAS  Google Scholar 

  94. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998;90(12):911–5.

    Article  PubMed  CAS  Google Scholar 

  95. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010;46(5):932–6.

    Article  PubMed  CAS  Google Scholar 

  96. Tseng M, Giri V, Watkins-Bruner D, Giovannucci E. Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control. 2009;20:1947–54.

    Article  PubMed  Google Scholar 

  97. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96(2):252–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, University of North Carolina-Chapel Hill, 2113 Physicians Office Building, Chapel Hill, NC, 27599-7235, USA

    James E. Ferguson III M.D., Ph.D.

  2. Division of Urology, Department of Surgery, UNC Lineberger Comprehensive Cancer Center, 2107 Physicians Office Building, Campus, 7235, Chapel Hill, NC, 27599-7235, USA

    Matthew E. Nielsen M.D.

  3. Department of Surgery, University of North Carolina, 2105 Physician’s Office Building, #7235, Chapel Hill, NC, 27599-7235, USA

    Eric M. Wallen & Raj S. Pruthi M.D., FACS

Authors
  1. James E. Ferguson III M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew E. Nielsen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric M. Wallen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raj S. Pruthi M.D., FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Ferguson III M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Ferguson, J.E., Nielsen, M.E., Wallen, E.M., Pruthi, R.S. (2013). Racial Disparities and the Global Picture. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_24

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation